2024
Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Zeidan A, Zhao R, Pierre-Victor D, Wang Y, Tepsick J, Lan Z, Salimi T. Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents. Blood 2024, 144: 5189-5189. DOI: 10.1182/blood-2024-205495.Peer-Reviewed Original ResearchAML-free survivalTreated with hypomethylating agentsOral hypomethylating agentsHypomethylating agentsMyelodysplastic syndrome patientsMyelodysplastic syndromeDEC-CClinical characteristicsMDS diagnosisNext treatmentMonths median follow-upRisk of AML transformationHigh-risk myelodysplastic syndromeReal-world treatment outcomesTreatment of adult patientsHypomethylating agent treatmentKaplan-Meier survival analysis methodMedian follow-upCox regression analysisReal-world studyAML transformationHMA therapyOral decitabineECOG 0Electronic health record database
2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare access
2021
Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use
Zeidan A, Divino V, DeKoven M, Shah D, Wang E, Bey D, Salimi T, Epstein R. Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use. Blood 2021, 138: 5030. DOI: 10.1182/blood-2021-144852.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeClinical Trials CommitteeHigher comorbidity burdenHMA therapySupportive careTrials CommitteeComorbidity burdenTreatment utilizationMean ageMyelodysplastic syndromeReal-world clinical practiceBaseline renal diseaseIntra-Cellular TherapiesLower comorbidity burdenAbsence of progressionRetrospective observational studyStem cell transplantationSimilar mean ageReal-world studyCurrent employmentFrailer patientsIQVIA PharMetricsSubcutaneous azacitidineIndex dateIntensive chemotherapyPredictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes. Journal Of Clinical Oncology 2021, 39: 7043-7043. DOI: 10.1200/jco.2021.39.15_suppl.7043.Peer-Reviewed Original ResearchPoor performance statusPoor PSHigh-risk myelodysplastic syndromeHMA therapyReal-world studyMyelodysplastic syndromeProgression/unacceptable toxicityPills/dayRetrospective cohort studyTreatment-related factorsMultivariable logistic regressionDirect medical costsHigh-risk groupOne-thirdGCSF useMore comorbiditiesEarly discontinuationPerformance statusUnacceptable toxicityCohort studyExcess blastsMultivariable analysisRefractory anemiaSEER-MedicareSurvival outcomes